NEW YORK (GenomeWeb) – Biocept plans to offer about $15 million of its common stock in a public offering, the firm said in documents filed with the US Securities and Exchange Commission on Wednesday. 

The company has not priced its offering, but said that it plans to offer about 6.3 million shares of its stock. Its shares closed at $2.52 in Wednesday trade on the Nasdaq. 

Aegis Capital and Feltl and Co. are listed as the underwriters on the offering. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.